Radiometals possess an exceptional breadth of decay properties and have been applied to
medicine with great success for several decades. The majority of current clinical use …

The eradication of cancer remains a vexing problem despite recent advances in our
understanding of the molecular basis of neoplasia. One therapeutic approach that has …

Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear
medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy …

The therapeutic utility of antibodies and their derivatives is achieved by various means. The
FDA has approved several targeted antibodies that disrupt signaling of various growth factor …

Pancreatic adenocarcinoma is one of the deadliest solid malignancies. A large proportion of
patients are diagnosed with locally advanced or metastatic disease at the time of …

Accumulating evidence suggests that the clinical efficacy of selected anticancer drugs,
including conventional chemotherapeutics as well as targeted anticancer agents, originates …

Simple Summary Monoclonal antibody-bearing radionuclides have been under clinical
investigation over the last two decades for their use in theranostic (diagnostic and …

The long-established notion that apoptosis would be immunologically silent, and hence it
would go unnoticed by the immune system, if not tolerogenic, and hence it would actively …

Pancreatic cancer is the fourth leading cause of cancer death in the United States. The
microenvironment of pancreatic cancer could be one of the “perfect storms” that support the …